Development of a Nomogram That Predicts Outcomes After Radical Cystectomy for Bladder Cancer Using Data from Siriraj Hospital, Thailand


Kanawut Sooksatian, M.D., Kantima Jongjitaree, M.D., Thitipat Hansomwong, M.D., Varat Woranisarakul, M.D., Patkawat Ramart, M.D., Siros Jitpraphai, M.D., Ekkarin Chotikawanich, M.D., Tawatchai Taweemonkongsap, M.D.*

Division of Urology, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.



*Corresponding author: Tawatchai Taweemonkongsap E-mail: thawatchai.taw@mahidol.ac.th

Received 16 January 2026 Revised 7 February 2026 Accepted 12 February 2026 ORCID ID: http://orcid.org/0000-0002-8969-0495 https://doi.org/10.33192/smj.v78i3.279910


ABSTRACT

Objective: This study aimed to develop and validate a prognostic nomogram to estimate individualized overall survival (OS) for bladder cancer patients in Thailand undergoing radical cystectomy (RC), using data from Siriraj Hospital. Materials and Methods: We retrospectively analyzed a cohort of 304 bladder cancer patients who underwent RC at Siriraj Hospital between 2012 and 2023. The patients were randomly allocated to the training (80%) and testing (20%) cohorts. Cox regression analyses were employed to identify predictors of OS from a range of clinical, pathological, and treatment-related variables. A prognostic nomogram was subsequently constructed and its performance was validated using the concordance index and the area under the receiver operating characteristic curve (AUC).

Results: The median patient age was 68 years and the majority of patients presented with muscle-invasive disease. The median duration of follow-up was 61 months, with a median overall survival of 51 months. Multivariate analysis identified five independent predictors of OS: age, preoperative glomerular filtration rate, type of urinary diversion, pathological N stage, and presence of lymphovascular invasion. The nomogram demonstrated strong predictive performance, with AUC values of 86.6% at 12 months, 84.0% at 36 months, and 76.6% at 60 months.

Conclusion: We have developed and validated a prognostic nomogram tailored for Thai bladder cancer patients undergoing RC. This tool provides individualized survival estimates and may be a valuable aid in patient counseling, risk stratification, and formulation of postoperative management strategies. Future multicenter validation and integration of molecular markers will enhance the clinical utility of the prognostic nomogram.

Keywords: Nomogram; cystectomy; bladder cancer; prognostic; survival (Siriraj Med J 2026;78(3):218-228)


INTRODUCTION

Bladder cancer is the 12th most commonly diagnosed malignancy globally, accounting for 573,278 new cases and 212,536 deaths in 2020.1 In Thailand, bladder cancer is among the top ten most common malignancies and ranks 9th in men. It accounts for approximately 2,700 deaths annually.2 Approximately 20%–40% of patients are diagnosed with muscle-invasive bladder cancer (MIBC), a condition that, if left untreated, is associated with a mortality rate of up to 85% within two years.3 Radical cystectomy (RC) remains the standard of care for MIBC; however, survival outcomes are heterogeneous. Reports from Europe and China indicate 5-year survival rates after RC ranging from 54.5% to 68%4, whereas data from Thailand suggest survival rates between 47.1% and 50%.5,6 In recent years, the field of uro-oncology has witnessed

an increasing emphasis on personalized medicine, with nomograms emerging as practical instruments for individualized risk prediction. Nomograms integrate multiple clinical and pathological parameters to generate patient-specific prognostic probabilities, thereby supporting shared decision-making between clinicians and their patients. Several studies have demonstrated that predictive models that incorporate demographic, pathological, and treatment variables can improve the accuracy of survival estimation following RC. Nevertheless, such models have been developed largely using data from Western populations, and their applicability to Southeast Asian cohorts remains uncertain.7-11 At Siriraj Hospital,

continuous clinical research on bladder cancer and radical cystectomy has been conducted over many years, resulting in the systematic collection of comprehensive clinical, pathological, and treatment-related data.12-14 This study was conducted to identify relevant prognostic factors and to construct a nomogram to predict overall survival (OS) in Thai bladder cancer patients following RC.


MATERIALS AND METHODS

This study was approved by the Institutional Review Board of the Siriraj Hospital Faculty of Medicine (SIRB) (COA no. Si 192/2024). The study was a single-center retrospective analysis of patients with bladder cancer aged ≥18 years who underwent radical cystectomy at the Division of Urology, Department of Surgery, Siriraj Hospital, between January 1, 2012 and December 31, 2023. Patients were excluded if they had incomplete medical records, metastatic bladder cancer, a concurrent malignancy, or had undergone palliative surgery or non-standard treatments such as alternative medicine. The variables analyzed were selected based on their clinical relevance and availability within the dataset. These variables encompassed demographic and clinical information, pathological tumor characteristics, surgical details and perioperative treatments. The factors were chosen and synthesized from published studies to ensure the inclusion of all potential variables that might influence survival outcomes.15-23 Collectively, these variables provide a

comprehensive overview of the patients’ clinical, surgical and oncological profiles. OS was defined as the time from the date of radical cystectomy to death from any cause. Patients who were alive at the time of last follow-up or had incomplete follow-up were not excluded; instead, they were censored at the date of last known follow-up. Survival outcomes were estimated using the Kaplan-Meier method. Prognostic factors for OS were identified using univariate and multivariate Cox proportional hazard models. Subsequently, a prognostic nomogram was developed based on the independent predictors identified in the multivariate analysis. The model’s validation was performed using the concordance index (C-index) and the area under the receiver operating characteristic curve (AUC) at 12, 36 and 60 months. All statistical analysed were conducted using SPSS software (version 21.0; IBM Corp., Armonk, NY, USA) and R program (version 4.3.3).


RESULTS

Patient characteristics

A total of 304 patients were included in the final analysis. The median age was 68 years and the cohort was predominantly male. Most of the patients presented with muscle-invasive disease and the predominant surgical approach was open radical cystectomy with ileal conduit diversion. A minority of patients received neoadjuvant

chemotherapy. The patient cohort was randomly divided into a training set (n=242, 80%) for model development and a testing set (n=62, 20%) for validation (Fig 1). There were no statistically significant differences in baseline characteristics, including age, disease stage and treatment patterns, between the two cohorts (all P-values > 0.05), confirming the appropriateness of the randomization. Baseline demographic, preoperative, surgical and oncological characteristics indicated that the majority of patients were older adults, predominantly male, with a median age approaching 70 years. Parameters such as renal function, body mass index and American Society of Anesthesiologists Physical Status (ASA) Classification System were comparable between the groups. A small proportion of patients received neoadjuvant chemotherapy. The majority of the patients underwent open radical cystectomy, with ileal conduit being the most common form of urinary diversion, followed by neobladder and other types. Most of the patients had muscle-invasive disease at the time of surgery and a subset had nodal involvement or lymphovascular invasion (LVI). Overall, no significant differences were observed between the training and testing cohorts, which supports the validity of the random allocation (Table 1 and Table 2). The median follow-up time for this study was 61 months,

and the median OS was 51 months.


Fig 1. Flow diagram for filtering and selecting patient records from the Siriraj database.


TABLE 1. Demographic and preoperative data.



Total data

Training data (N = 242)

Testing data (N = 62)

P-value

Age (Years)

67.5±14.0

68±14.0

66.5±12.8

0.482

Age group, n (%)





<60

63(20.7)

53(21.9)

10(16.1)

0.103

60-69

112(36.8)

81(33.5)

31(50.0)


70-79

97(31.9)

80(33.1)

17(27.4)


>80

32(10.5)

28(11.6)

4(6.5)


Sex, n (%)




0.303

Male

240(78.9)

194(80.2)

46(74.2)


Female

64(21.1)

48(19.8)

16(25.8)


BMI

23.4±6.0

23.6±6.1

22.4±5.3

0.076

BMI, n (%)





<18.5

28(9.2)

22(9.1)

6(9.7)

0.515

18.5-25

174(57.2)

135(55.8)

39(62.9)


>25

102(33.6)

85(35.1)

17(27.4)


ASA classification, n (%)




0.954

1

57(18.8)

45(18.6)

12(19.4)


2

167(54.9)

134(55.4)

33(53.2)


>=3

80(26.3)

63(26.0)

17(27.4)


Pre-operative GFR

57.1±32.0

59.0±30.0

49.5±33.3

0.050

Pre-operative GFR, n (%)





>60

135(44.4)

114(47.1)

21(33.9)

0.169

30-60

134(44.1)

102(42.1)

32(51.6)


<30

80(26.3)

26(10.7)

9(14.5)


Pre-operative Hydronephrosis, n (%)




0.170

No

156(51.3)

129(53.3)

27(43.5)


Yes

148(48.7)

113(46.7)

35(56.5)


Primary tumor size, n (%)




0.010

<4cm

118(38.8)

104(43.0)

14(22.6)


>=4cm

132(43.4)

97(40.1)

35(56.5)


Unknown

54(17.8)

41(16.9)

13(21.0)


Tumor number, n (%)




0.588

Solitary

176(58.3)

143(59.6)

33(53.2)


Multiple

105(34.5)

80(33.3)

25(40.3)


Diffuse

21(6.9)

17(7.1)

4(6.5)


Tumor morphology, n (%)




0.897

Papillary

160(52.6)

129(53.3)

31(50.0)


Sessile

93(30.6)

73(30.2)

20(32.3)


Flat lesion

51(16.8)

40(16.5)

11(17.7)


Primary tumor location, n (%)





Trigone

55(18.3)

37(15.5)

18(29.0)

0.014

Dome

73(24.3)

56(23.4)

17(27.4)

0.514

Lateral wall

195(64.8)

156(65.3)

39(62.9)

0.870

Anterior wall

81(26.9)

60(25.1)

21(33.9)

0.165

Posterior wall

147(48.8)

116(48.5)

31(50.0)

0.837

Bladder neck

58(19.3)

42(17.6)

16(25.8)

0.143

Time Diagnosis to surgery

91±118.0

91±117.0

90+119.0

0.661

Time Diagnosis to surgery, n (%)





<=90 day

150(50)

119(50)

31(50.0)

1.000

>90

150(50)

119(50)

31(50.0)


Clinical T stage, n (%)




0.713

Localized disease (stage <=2)

115(37.8)

92(38)

22(35.5)


Locally advanced disease (stage>3)

190(62.5)

150(62)

40(64.5)


Abbreviations: BMI, body mass index; ASA, American Society of Anesthesiologists Physical Status (ASA) Classification System; GFR, glomerular filtration rate;


TABLE 2. Surgical and Oncological data.



Total data

Training data

Testing data

P-value


(N = 304)

(N = 242)

(N = 62)


Surgical approach, n (%)




0.901

Open

241 (79.3)

193 (79.8)

48 (77.4)


Laparoscopic

24 (7.9)

19 (7.9)

5 (8.1)


Robotic assisted

39 (12.8)

30(12.4)

9 (14.5)


Type of diversion, n (%)




0.574

Ileal conduit

252 (82.9)

198 (81.8)

54 (87.1)


Neobladder

29 (9.5)

24 (9.9)

5 (8.1)


Ureterostomy

23 (7.6)

20 (8.3)

3 (4.8)


Histology, n (%)




0.202

Urothelial carcinoma

289 (95.1)

232 (95.9)

57 (91.9)


Non-urothelial carcinoma

15 (4.9)

10 (4.1)

5 (8.1)


Pathologic T stage, n (%)




0.448

T0

12 (3.9)

11 (4.5)

1 (1.6)


T1

24 (7.9)

17 (7.0)

7 (11.3)


T2

93 (30.6)

78 (32.2)

15 (24.2)


T3

115 (37.8)

90 (37.2)

25 (40.3)


T4

60 (19.7)

46 (19)

14 (22.6)


N stage, n (%)




0.190

N0

195 (64.1)

156 (64.5)

39 (62.9)


N1

45 (14.8)

40 (16.5)

5 (8.1)


N2

50 (16.4)

36 (14.9)

14 (22.6)


N3

11 (3.6)

10 (4.1)

4 (6.5)


Lymphovascular invasion, n (%)




0.739

No

161 (52.7)

127 (52.5)

34 (54.8)


Yes

143 (47.0)

115 (47.5)

28 (45.2)


Margin positive, n (%)




0.820

No

242 (79.6)

192 (79.3)

50 (80.6)


Yes

62 (20.4)

50 (20.7)

12 (19.4)


Carcinoma in situ, n (%)




0.325

No

252 (82.9)

198 (81.8)

54 (87.1)


Yes

52 (17.1)

44 (18.2)

8 (12.9)


Chemotherapy





Pre-operative

90 (29.6)

76 (31.4)

14 (22.6)

0.174

Post-operative

46 (15.2)

38 (15.8)

8 (12.9)

0.575

Radiation therapy, n (%)





Pre-operative

1 (0.3)

1 (0.4)

0 (0)

1.000

Post-operative

12 (4.0)

11 (4.6)

1 (1.6)

0.471

Identification of prognostic factors

Univariate analysis was performed on 21 potential prognostic factors. Of these, 11 were significantly associated with OS at a significance threshold of P <

0.15. These factors included age, body mass index (BMI), preoperative glomerular filtration rate (GFR), presence of

hydronephrosis, tumor location, surgical approach, type of urinary diversion, pathological T and N stage, LVI, and margin status (Table 3). Subsequent multivariate Cox regression analysis identified five independent predictors of OS: age, preoperative GFR, type of urinary diversion, pathologic N stage, and LVI (Table 4).


TABLE 3. Predictive factors of 5-year overall survival.


Factor Univariate analysis

Unadjusted HR (95%CI) P-value

Age







<60

Reference





60-69

1.043

0.632

1.720

0.870


70-79

1.207

0.734

1.985

0.459


>80

2.195

1.222

3.942

0.009

Sex







Male

Reference





Female

0.892

0.567

1.404

0.622

BMI







<18.5

Reference





18.5-25

0.759

0.427

1.351

0.349


>25

0.607

0.330

1.118

0.109

ASA







1

Reference





2

1.361

0.835

2.217

0.217


>=3

1.478

0.849

2.573

0.167

Pre-operative GFR

>60

Reference




30-60

1.651

1.119

2.436

0.012

<30

2.495

1.476

4.216

0.001

Pre-operative hydronephrosis

No

Reference




Yes

1.348

0.948

1.918

0.097

Primary tumor size

<4cm

Reference




>=4cm

0.992

0.671

1.466

0.966

Unknown

0.936

0.571

1.533

0.793

Tumor number





Solitary

Reference




Multiple

1.200

0.824

1.749

0.341

Diffuse

1.101

0.529

2.293

0.797

Tumor morphology





Papillary

Reference




Sessile

0.934

0.625

1.397

0.741

Flat lesion

0.782

0.473

1.294

0.339

Primary tumor location

Trigone

1.345

0.855

2.117

0.200

Dome

1.035

0.686

1.564

0.869

Lateral wall

1.193

0.810

1.756

0.372

Bilateral lateral wall

1.234

0.661

2.304

0.509

Anterior wall

1.126

0.757

1.673

0.558

Posterior wall

1.183

0.830

1.685

0.353

Bladder neck

1.394

0.897

2.165

0.140


TABLE 3. Predictive factors of 5-year overall survival. (Continue)


Factor

Univariable analysis

Unadjusted HR (95%CI)

P-value

Time Diagnosis to surgery

<=90 day Reference

>90 0.988 0.687 1.422 0.949


Surgical approach

Open


Reference


Laparoscopic

1.007

0.540

1.880

0.982

Robotic assisted

0.371

0.163

0.845

0.018

Type of diversion





Ileal conduit

Reference




Neobladder

0.339

0.138

0.833

0.018

Ureterostomy

2.426

1.408

4.181

0.001

Histology

Urothelial carcinoma

Reference




Non-urothelial carcinoma

0.620

0.229

1.680

0.347

Pathologic T stage

T0

Reference




T1

4.330

0.541

34.630

0.167

T2

2.974

0.404

21.910

0.285

T3

7.644

1.058

55.250

0.044

T4

8.765

1.197

64.200

0.033

N stage





N0

Reference




N positive

3.553

2.483

5.084

<0.001

Lymphovascular invasion

No

Reference




Yes

2.656

1.846

3.821

<0.001

Margin positive





No

Reference




Yes

1.687

1.131

2.514

0.010

Carcinoma in situ

No

Reference




Yes

1.093

0.699

1.710

0.695

Chemotherapy





Pre-operative

0.769

0.507

1.167

0.216

Post-operative

0.799

0.490

1.303

0.368

Radiation therapy





Pre-operative

0.000

0.000

0.000

0.995

Post-operative

1.201

0.586

2.461

0.617


Abbreviations: BMI, body mass index; ASA, American Society of Anesthesiologists Physical Status (ASA) Classification System; GFR, glomerular filtration rate;


TABLE 4. Predictive factors of 5-year overall survival.


BMI

Factor

Univariable analysis

Unadjusted HR (95%CI)

Multivariable analysis

P-value Adjusted HR (95%CI)

P-value

Age


<60

Reference


60-69

1.043

0.632

1.720

0.870

1.26

0.76

2.10

0.375

70-79

1.207

0.734

1.985

0.459

1.45

0.86

2.44

0.164

>80

2.195

1.222

3.942

0.009

3.33

1.75

6.34

0.000


<18.5

18.5-25

Reference

0.759


0.427


1.351


0.349

>25

0.607

0.330

1.118

0.109

Pre-operative GFR

>60


Reference








30-60

1.651

1.119

2.436

0.012

1.220

0.807

1.845

0.346

<30

2.495

1.476

4.216

0.001

1.935

1.093

3.428

0.024

Pre-operative hydronephrosi No

Yes

s

Reference 1.348


0.948


1.918


0.097

Primary tumor location

Bladder neck

1.394

0.897

2.165

0.140





Surgical approach

Open


Reference








Laparoscopic

1.007

0.540

1.880

0.982





Robotic assisted

0.371

0.163

0.845

0.018





Type of diversion Ileal conduit


Reference








Neobladder

0.339

0.138

0.833

0.018

0.44

0.18

1.09

0.076

Ureterostomy

2.426

1.408

4.181

0.001

1.90

1.07

3.39

0.029

Pathologic T stage

T0


Reference








T1

4.330

0.541

34.630

0.167





T2

2.974

0.404

21.910

0.285





T3

7.644

1.058

55.250

0.044





T4

8.765

1.197

64.200

0.033





N stage N0


Reference








N positive

3.553

2.483

5.084

<0.000

2.98

1.96

4.54

<0.001

Lymphovascular invasion

No

Yes

Reference

2.656


1.846


3.821


<0.000


1.88


1.22


2.89


0.004

Margin positive









No Yes

Reference 1.687


1.131


2.514


0.010

Abbreviations: BMI, body mass index; GFR, glomerular filtration rate;

Development and validation of a prognostic nomogram

A nomogram was constructed incorporating the five independent prognostic factors. This nomogram uses a point-based scoring system to estimate the 1-, 3-, and 5-year OS probabilities for individual patients (Fig 2). The predictive accuracy of the nomogram was confirmed through C-index and ROC analysis. The model demonstrated a high discriminatory power, with AUC values of 86.61% (95% CI 77.2–96.0) at 12 months,

83.97% (95% CI 73.0–94.9) at 36 months, and 76.56%

(95% CI 62.0–91.1) at 60 months (Fig 3).

DISCUSSION

This study represents the first initiative to develop a prognostic nomogram specifically for bladder cancer patients undergoing RC in Thailand. The model identified age, preoperative GFR, type of urinary diversion, lymph

node involvement (N stage) and LVI as key independent prognostic factors. These findings are consistent with the results of earlier studies conducted in Western and Asian populations. It should be noted that pathological T stage including subgroup analysis comparing pT0–2 versus pT3–4 did not retain its significance in the final multivariate model, an observation likely attributable to the multicollinearity with N stage and LVI, both of which more directly reflect tumor aggressiveness and the potential for systemic dissemination.

Each variable included in the final model has previously been established as a powerful prognostic marker in bladder cancer. Age is a known independent factor associated with both cancer-specific and all-cause mortality, as older patients typically present with more comorbidities and reduced physiological reserve.7 N stage remains one of the most consistent predictors of a poor


Fig 2. Nomogram predicting overall survival probability of 1- 3- and 5-years after radical cystectomy. Variables include Age, Pre-operative glomerular filtration rate (GFR), Type of diversion, Pathologic N stage, and Lympho-vascular invasion.


Fig 3. Validation of the nomogram.

prognosis, given that nodal metastasis is indicative of systemic spread and necessitates aggressive multimodal therapy.11 A reduced preoperative GFR not only restricts eligibility for cisplatin-based chemotherapy but also serves as an indicator of overall health status, which can impact long-term outcomes.17 Furthermore, LVI is a well-established marker of aggressive tumor biology and metastatic potential.21 The type of diversion is a significant factor in this study. Patients undergoing neobladder reconstruction typically have fewer comorbidities and a better baseline functional status compared to those receiving other types of diversion, which may contribute to better survival outcomes. However, we still included this factor in the development of the nomogram because the type of diversion is an important postoperative factor applicable to every patient after radical cystectomy.8

Neoadjuvant chemotherapy (NAC), despite being recommended by international guidelines for muscle-invasive bladder cancer, was not a significant predictor in our model. This finding is in alignment with a large SEER cohort study of T2-4N0-3M0 MIBC, in which, after the inverse probability of treatment weighting, NAC did not confer a statistically significant OS advantage over adjuvant chemotherapy. However, subgroup analysis revealed that in patients without lymph node involvement (N0), NAC was associated with superior OS and cancer-specific survival compared to adjuvant chemotherapy, suggesting that nodal status may mediate the benefit of NAC in MIBC. The lack of significance in our cohort may be due to selection bias, as patients receiving NAC often present with more advanced disease or worse baseline characteristics, potentially offsetting the therapeutic benefit. Additionally, variability in chemotherapy regimens, incomplete treatment courses, and the absence of a centralized response evaluation may dilute the observed impact. Immune checkpoint inhibitors were not included in the present analysis, as their use was limited to the most recent 2–3 years and involved a very small number of patients, precluding meaningful statistical analysis.

In our cohort, the low uptake of NAC and inconsistencies in treatment documentation could further diminish statistical power. Moreover, our study did not include data on pathologic downstaging post-NAC, which is a critical intermediate endpoint correlated with long-term benefit.24 Consequently, the non-significance of NAC in this study does not imply a lack of benefit, but rather highlights the challenges of capturing its value in retrospective, real-world datasets.

The nomogram developed in this study provides a clinically practical tool for individualized risk prediction. It enables clinicians to estimate OS at multiple time

points, thereby enhancing prognostic counseling, tailoring surveillance strategies, and informing treatment planning. Patients identified as high-risk by the model may be considered for more intensive follow-up or additional therapeutic interventions.

Several limitations of this study should be acknowledged. The retrospective single-center design limits the generalizability of the findings, and the presence of missing data could have influenced variable selection and statistical significance. Certain potentially relevant prognostic factors, such as smoking status, nutritional parameters and molecular or genetic markers, were not available for analysis. Furthermore, the study lacks external validation in an independent cohort. The relatively small number of patients who received NAC may also have limited the statistical power to detect a survival benefit associated with this treatment.

In practical application, this nomogram can be implemented as a web-based or electronic medical record-integrated tool, allowing clinicians to input patient-specific variables to generate immediate survival estimates. This can help guide patient counseling and facilitate risk-adapted follow-up protocols, ultimately contributing to improved patient outcomes and more efficient resource allocation.


CONCLUSION

We have successfully developed and validated a nomogram that predicts OS in bladder cancer patients following RC at Siriraj Hospital. This model provides clinicians with an individualized prediction tool tailored to the Thai population, which can assist in shared decision-making and postoperative planning. Future research should focus on prospective multicenter validation and the integration of molecular biomarkers to strengthen the reliability and clinical utility of the model.


ACKNOWLEDGEMENT

The authors would like to express their gratitude to Dr. Saowalak Hunnangkul and Terasut Numwong for valuable assistance and support in this study.

DECLARATIONS

Grants and Funding Information

None.

Conflict of Interest

All authors declare no personal or professional conflicts of interest, and no financial support from the companies that produce and/or distribute the drug, devices, or materials described in this report.

Registration Number of Clinical Trial

None.

Author Contributions

Conceptualization and methodology: K.S., T.T., T.H.; Investigation: K.S., V.W.; Formal analysis: K.S., K.J., P.R.; Visualization and writing—original draft: K.S., T.T.; Writing-review and editing: T.T., E.C., S.J.; Supervision: T.T.

Ethical Approval Statement

This study was approved by the Institutional Review Board of the Siriraj Hospital Faculty of Medicine (SIRB) (COA no. Si 192/2024).

Use of Artificial Intelligence

No artificial intelligence tools or technologies were used in the writing and analysis.

REFERENCES

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.

  2. Cancer. IAfRo. Thailand fact sheet: GLOBOCAN 2020. . Lyon, France: International Agency for Research on Cancer; 2020.

  3. Aboumarzouk OM, Drewa T, Olejniczak P, Chlosta PL. Laparoscopic versus open radical cystectomy for muscle-invasive bladder cancer: a single institute comparative analysis. Urol Int. 2013;91(1):109-12.

  4. Zhang ZL, Dong P, Li YH, Liu ZW, Yao K, Han H, et al. Radical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients. Chin J Cancer. 2014;33(3):165-71.

  5. Ramart P, Chaiyaprasithi B, Pradniwat K, Ratanarapee S, Amornvesukit T, Taweemongkongsap T, et al. Outcome of open radical cystectomy with pelvic lymph node dissection for bladder urothelial cancer in Siriraj hospital between 1998-2003. Insight Urology. 2010;31(1):27-39.

  6. Siriboonpipattana N, Nualyong C, Taweemonkongsap T, Leewansangtong S, Ramart P, Amornvesukit T. The Oncologic Outcome of Laparoscopic Radical Cystectomy for Invasive Bladder Cancer in Siriraj Hospital Between 2005-2013. Siriraj Medical Journal. 2017;69(6):377-83.

  7. Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG, et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res. 2006;12(22):6663-76.

  8. Yang Z, Bai Y, Liu M, Hu X, Han P. Development and validation of a prognostic nomogram for predicting cancer-specific survival after radical cystectomy in patients with bladder cancer:A population-based study. Cancer Med. 2020;9(24): 9303-14.

  9. Osawa T, Abe T, Takada N, Ito YM, Murai S, Shinohara N. Validation of the nomogram for predicting 90-day mortality after radical cystectomy in a Japanese cohort. Int J Urol. 2018;25(7): 699-700.

  10. Liu P, Xu L, Chen G, Shi B, Zhang Q, Chen S. Nomograms for predicting survival in patients with micropapillary bladder cancer: a real-world analysis based on the surveillance, epidemiology, and end results database and external validation in a tertiary center. BMC Urol. 2023;23(1):16.

  11. Wang J, Wu Y, He W, Yang B, Gou X. Nomogram for predicting overall survival of patients with bladder cancer: A population-based study. Int J Biol Markers. 2020;35(2):29-39.

  12. Veerakulwatana S, Suk-Ouichai C, Taweemonkongsap T, Chotikawanich E, Jitpraphai S, Woranisarakul V, et al. Perioperative factors and 30-day major complications following radical cystectomy: A single-center study in Thailand. Heliyon. 2024;10(13):e33476.

  13. Mahalelakul A, Assavavirojekul P, Leewansangtong S, Woranisarakul V, Hansomwong T, Srinualnad S. Outcomes of Robot-assisted Radical Prostatectomy in Men Aged 75 Years Old or Older: A Single-center Study in Thailand. Siriraj Medical Journal. 2025; 77(1):22-8.

  14. Sornthai W, Teyateeti A, Taweemonkongsap T, Jitpraphai S, Woranisarakul V, Jongjitaree K, et al. Preoperative myosteatosis and perioperative serum chloride levels predict 180 day major complications after radical cystectomy. Sci Rep. 2025;15(1):3184.

  15. Lee CT, Dunn RL, Chen BT, Joshi DP, Sheffield J, Montie JE. Impact of body mass index on radical cystectomy. J Urol. 2004;172(4 Pt 1):1281-5.

  16. Mayr R, May M, Martini T, Lodde M, Pycha A, Comploj E, et al. Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder. BJU Int. 2012;110(6 Pt B):E222-7.

  17. Kim D, Nam W, Kyung YS, You D, Jeong IG, Hong B, et al. Effect of decreased renal function on poor oncological outcome after radical cystectomy. Investig Clin Urol. 2023;64(4):346-52.

  18. Cheng L, Neumann RM, Scherer BG, Weaver AL, Leibovich BC, Nehra A, et al. Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion. Cancer. 1999;85(12):2638-47.

  19. Chen H, Hong Y, Yu B, Ruiqian L, Jun L, Hongyi W, et al. Retrospective analysis of bladder cancer morphology and depth of invasion under cystoscopy. BMC Urol. 2022;22(1):12.

  20. Kimura S, Mari A, Foerster B, Abufaraj M, Vartolomei MD, Stangl-Kremser J, et al. Prognostic Value of Concomitant Carcinoma In Situ in the Radical Cystectomy Specimen: A Systematic Review and Meta-Analysis. J Urol. 2019;201(1): 46-53.

  21. Kikuchi E, Margulis V, Karakiewicz PI, Roscigno M, Mikami S, Lotan Y, et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol. 2009;27(4):612-8.

  22. Chang SS, Hassan JM, Cookson MS, Wells N, Smith JA, Jr. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol. 2003;170(4 Pt 1): 1085-7.

  23. Fallara G, Di Maida F, Bravi CA, De Groote R, Piramide F, Turri F, et al. A systematic review and meta-analysis of robot-assisted vs. open radical cystectomy: where do we stand and future perspective. Minerva Urol Nephrol. 2023;75(2):134-43.

  24. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859-66.